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Abstract
Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation 
can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway activation are 
critical. The main focus of our work was to develop a gene expression signature that is predictive of RAS pathway 
dependence.
Methods: We used the coherent expression of RAS pathway-related genes across multiple datasets to derive a RAS 
pathway gene expression signature and generate RAS pathway activation scores in pre-clinical cancer models and 
human tumors. We then related this signature to KRAS mutation status and drug response data in pre-clinical and 
clinical datasets.
Results: The RAS signature score is predictive of KRAS mutation status in lung tumors and cell lines with high (> 90%) 
sensitivity but relatively low (50%) specificity due to samples that have apparent RAS pathway activation in the absence 
of a KRAS mutation. In lung and breast cancer cell line panels, the RAS pathway signature score correlates with pMEK 
and pERK expression, and predicts resistance to AKT inhibition and sensitivity to MEK inhibition within both KRAS 
mutant and KRAS wild-type groups. The RAS pathway signature is upregulated in breast cancer cell lines that have 
acquired resistance to AKT inhibition, and is downregulated by inhibition of MEK. In lung cancer cell lines knockdown 
of KRAS using siRNA demonstrates that the RAS pathway signature is a better measure of dependence on RAS 
compared to KRAS mutation status. In human tumors, the RAS pathway signature is elevated in ER negative breast 
tumors and lung adenocarcinomas, and predicts resistance to cetuximab in metastatic colorectal cancer.
Conclusions: These data demonstrate that the RAS pathway signature is superior to KRAS mutation status for the 
prediction of dependence on RAS signaling, can predict response to PI3K and RAS pathway inhibitors, and is likely to 
have the most clinical utility in lung and breast tumors.
Background
Signal transduction in response to growth factor receptor
activation in tumors is a complex process that involves
downstream signaling through the RAS (reviewed in [1])
and PI3K (reviewed in [2]) signaling pathways. These
pathways are among the best characterized in cancer
biology, involve a network of protein and lipid kinases
working in concert to regulate diverse biological outputs,
and can be activated by multiple mechanisms including
gene amplification and somatic mutation. Understanding
the role of these pathways in cancer biology has been
enabled through the characterization of alterations in
component pathway nodes including amplification of
receptor tyrosine kinases like Her and EGFR, and genetic
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changes in PTEN, PIK3CA, AKT, KRas and BRAF, all of
which have been shown to contribute to the cancer phe-
notype. The RAS and PI3K pathways are thought to work
in parallel and/or through cross-talk such that optimal
therapeutic benefit can be achieved only through inhibi-
tion of both pathways. As AKT is a central node in the
PI3K pathway and MEK is a central node in the RAS
pathway, developing inhibitors of AKT and MEK is a
strategy being pursued by the pharmaceutical industry
[3].
Recent clinical data have emerged demonstrating that
activating mutations in the KRAS gene predict resistance
to treatment with inhibitors of the epidermal growth fac-
tor receptor (EGFR). For example, KRAS mutations are
associated with decreased disease control rate, shorter
progression-free survival and reduced overall survival in
p a t i e n ts  wi t h  a d va n c ed  o r  m e tas t a t i c  c o l o r ect a l  ca n c e r
treated with the EGFR-targeting antibodies cetuximab or
panitumumab [4-6]. In non-small cell lung cancer, the
relationship between KRAS mutation and response to
EGFR inhibitors is less clear. Response rates in patients
that do not harbor an activating mutation in EGFR are
low, and mutations in KRAS and EGFR rarely occur in
the same tumor. As such, there has been no clear rela-
tionship between KRAS mutation status and clinical out-
comes in patients treated with the EGFR tyrosine kinase
inhibitors gefitinib or erlotinib [7]. Therefore, while alter-
ations in specific RAS pathway components have lead to
an increased understanding of the molecular drivers of
r e s p o n s e  t o  E G F R  i n h i b i t i o n  i n  c o l o r e c t a l  c a n c e r ,  t h e
relationship between KRAS mutation, RAS pathway
dependence, and drug response is less clear in NSCLC
and other tumor types.
Given the importance of KRAS activation for the selec-
tion of targeted cancer therapies, it is crucial that optimal
methods are developed to measure the activation state of
RAS in tumors. Due to the numerous genetic changes in
tumors and the complexity of mechanisms underlying
RAS pathway activation, a more comprehensive means of
assessing RAS pathway activation status would be prefer-
able. One way to enable a more comprehensive readout of
pathway activity is to identify gene expression profiles
that are indicative of pathway activation status. A gene
expression signature-based pathway readout may be
more appropriate than relying on a single indicator of
pathway activity, as alterations in multiple signaling com-
ponents could lead to pathway activation and result in
similar downstream effects (for example, mutations in B-
raf also lead to pathway activation and may lead to resis-
tance to therapies targeting EGFR in colorectal cancer
[4,5,8]).
Recent gene expression profiling efforts have identified
pathway signatures that can be applied broadly across dif-
ferent datasets to monitor pathway activity. Moreover,
recent studies have shown that pathway signatures can
predict drug response in vitro and stratify tumors accord-
ing to predicted pathway status [9-13]. Gene expression
signatures could have additional benefit as pathway bio-
markers, as these signatures could be used for both pre-
treatment patient stratification (i.e. prospectively
identifying patients harboring tumors that are dependent
on RAS signaling) and pharmacodynamic evaluation (i.e.
monitoring pathway inhibition post-treatment). How-
ever, comparing pathway signatures to one another and
assessing their robustness in independent datasets can be
hampered by the use of heterogeneous microarray profil-
ing and analysis methods [14-16]. Given the clinical
importance of understanding RAS pathway activation
and its relationship to drug response, our main goal was
to develop a gene expression signature indicative of RAS
pathway activity in human tumors that is robust and
translatable across multiple tumor types and datasets.
With such a tool in hand, it would be possible to assign a
RAS activation score to tumors for the purposes of drug
response prediction and pharmacodynamic assessment.
Through an integrated analysis of literature data and
internal datasets incorporating both cell line models and
human tumors, we identified a RAS pathway signature
consisting of 147 genes that is coherently expressed
across multiple datasets. The RAS pathway signature has
a high sensitivity for detecting KRAS mutant cell lines
and human tumors, but also identifies samples that have
apparent RAS pathway activation in the absence of a
KRAS mutation. We show that baseline levels of the RAS
pathway signature predict resistance to AKT inhibition
and sensitivity to MEK inhibition in cell line panels inde-
pendent of KRAS mutation status, that the signature is
downregulated by MEK inhibition, and that the signature
is a better predictor of RAS pathway dependence com-
pared to KRAS mutation status in lung cancer cell lines.
In human tumors, the RAS signature is coherent across
multiple tumor types, is elevated in clinical subtypes not
known to harbor KRAS mutations (i.e. ER negative breast
cancer), and predicts resistance to cetuximab in meta-
static colorectal cancer. These data demonstrate that the
RAS signature significantly expands the population of
human tumors exhibiting RAS pathway deregulation, and
has potential clinical utility in identifying lung and breast
tumors where RAS pathway dependence should be con-
sidered when choosing appropriate targeted therapies.
Results and Discussion
Development of a novel RAS pathway gene expression 
signature
We were interested in the possibility that quantification
of Ras-dependent gene expression would provide a better
m e a s u r e  o f  R a s  a c t i v i t y  i n  c a n c e r  c e l l s  t h a n  m u t a t i o n
analysis. To develop a gene expression signature of RasLoboda et al. BMC Medical Genomics 2010, 3:26
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activity, we started with published RAS pathway signa-
tures generated using different model systems by three
laboratories [9,12,17]. All of the signatures were split into
two opposite "arms" - the "up" arm, which is upregulated,
and the "down" arm, which is downregulated, as signaling
through the RAS pathway increases. While these three
signatures report on a similar biological state, the signa-
tures contain different genes, and the expression of many
of the genes within each signature did not adhere to the
expected correlation pattern in several publicly available
tumor profiling datasets (Additional file 1, Figure S1).
Therefore, these signatures may not provide a robust
measurement in clinical samples.
We then identified a new RAS pathway signature by
assembling the genes from the up arms of these three sig-
natures into a "superset" of 812 genes. By assessing the
correlation of genes within this superset in publicly avail-
able lung, breast, and colon gene expression datasets, we
identified a coherent subset of genes that were signifi-
cantly correlated with each other in all datasets (see
m e t h o d s ;  A d d i t i o n a l  f i l e  2 ,  F i g u r e  S 2 ) .  T h e  g e n e s  t h a t
belonged to this subset across all the datasets were
selected as the up arm of our RAS pathway signature.
Genes significantly anticorrelated with the up arm across
a lung cancer cell line panel were then selected as the
down arm. This procedure resulted in the identification
of a 147 gene signature (105 up genes, 42 down genes,
Additional file 3, Table S1) that we call the "RAS pathway
signature". At least 20 genes in this signature are estab-
lished components of the the RAS-MEK-ERK signaling
network. These include multiple transcription factors
and targets of ERK signaling such as FOS and IER3 as well
as MAPK-phosphatases and sprouty genes involved in
feedback inhibition of MEK/ERK signaling (dual specific-
ity phosphatases 6 (DUSP6), DUSP1, DUSP4, DUSP5 and
SPRY4)) [18].
RAS pathway signature coherence
We first assessed the coherence of our RAS pathway sig-
nature in publicly available colon, lung, and breast tumor
datasets that were independent of those used to discover
the signature (see materials and methods). The coherence
test incorporates the knowledge that a signature is com-
prised of two oppositely regulated components (i.e. up
and down arms) in order to assess the robustness of the
signature when it is analyzed in independent datasets.
The signature was significantly coherent across all tumor
types, with each of these datasets having a p-value less
than 10-5 for the coherence test (Additional file 4, Table
S2). We conclude that the RAS pathway signature is a
robust signature that is translatable across tumor types,
including tumors in which the prevalence of mutations in
KRAS is low (i.e. breast cancer).
RAS pathway signature score calculation and prediction of 
KRAS mutational status
We calculated a composite score for our RAS pathway
signature as described in [19]. Briefly, we used the follow-
ing unweighted averaging scheme to calculate signature
scores: First, individual datasets were mean normalized
and gene expression for each gene in each sample was
expressed as the log(10) ratio relative to the mean. Signa-
ture scores were then determined by calculating the mean
log(10) ratio of genes in the "up" branch minus the mean
log(10) ratio of genes in the "down" branch.
We then assessed the ability of the RAS pathway signa-
ture score to predict KRAS mutation status in lung can-
cer cell lines (n = 50), breast cancer cell lines (n = 32), and
lung tumors (n = 48). Using a signature score of zero
(mean value across a population) as the threshold, 14/15
lung cancer cell lines, 2/2 breast cancer cell lines, and 11/
12 lung tumors with KRAS mutations had high signature
scores (Figure 1). Interestingly, a significant number of
KRAS wild-type cell lines and tumors exhibited high RAS
pathway signature scores (40% of wild-type lung cell
lines, 30% of wild-type breast cell lines, and 53% of wild-
type lung tumors), suggesting that these samples have
upregulated RAS signaling through another mechanism.
Thus, in these datasets the RAS pathway signature is a
high sensitivity but low specificity of predictor of KRAS
mutation status, indicating that using the RAS pathway
signature as a predictor of RAS pathway deregulation
would significantly increase the population of "RAS path-
way active" lung or breast tumors compared to using
KRAS mutation status.
Baseline level of RAS pathway signature correlates with 
drug sensitivity independent of KRAS mutation status
We next assessed the relationship between baseline levels
of the RAS pathway signature and cell line sensitivity to
small molecule inhibitors of AKT and MEK in indepen-
dent experiments involving panels of lung cancer (n = 93)
and breast cancer (n = 69) cell lines. Across lung cancer
cell lines, elevated RAS pathway signature score at base-
line was significantly correlated with sensitivity to a small
molecule inhibitor of MEK1 and MEK2 (PD325901; Fig-
ure 2A). Interestingly, this correlation was observed
within both KRAS mutant and KRAS wild-type cell lines.
In addition, two lung cancer cell lines with KRAS muta-
tions exhibited low RAS pathway signature scores and
were resistant to MEK inhibition, suggesting that while
they are KRAS mutant, they are not dependent on RAS
signaling. In breast cancer cell lines, only 3 of which are
known to harbor a KRAS mutation, baseline levels of the
RAS pathway signature were again significantly corre-
lated with sensitivity to MEK inhibition, and were also
significantly correlated with resistance to a small mole-
cule inhibitor of AKT (MK-2206; Figure 2B, 2C).Loboda et al. BMC Medical Genomics 2010, 3:26
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In addition to gene expression profiling of these cell
lines, we also assessed the activation state of key RAS
pathway signaling nodes in both the lung and breast can-
cer cell line panels using reverse phase protein microar-
rays [20]. The RAS pathway signature score was
significantly correlated with pMEK and pERK in both
lung and breast cancer cell lines, with the highest correla-
tion observed for pMEK in br east cancer lines (F igure
2D). Taken together, these results suggest that the RAS
pathway signature integrates information transmitted
through upstream activation of RAS signaling, correlates
with phospho-protein readouts of RAS signaling, and is a
better predictor of response to agents targeting MEK and
A K T  c o m p a r e d  t o  K RA S  m u t a t i o n  s t a t u s  i n  l u n g  a n d
breast cancer cell lines.
Acquired resistance to AKT inhibition is associated with 
upregulated RAS signature
To further explore the relationship between the RAS
pathway signature and resistance to AKT inhibition, we
generated a resistant version of an MK-2206 sensitive
breast cancer cell line (ZR-75-1) by exposure to increas-
ing concentrations of MK-2206 for a period of 7 months
(Figure 3A). ZR-75-1 cells harbor an inactivating muta-
tion in the tumor suppressor PTEN, which may underlie
the initial dependence on AKT signaling for survival.
Cells exposed to vehicle for 7 months remained sensitive
to MK-2206 (Figure 3B). We analyzed mRNA expression
profiles of ZR-75-1R, compared these to profiles of the
parental cells, and established a gene signature of
acquired AKT resistance. We then assessed the associa-
tion between acquired resistance and the RAS pathway
signature score by comparing RAS pathway signature
score levels in the resistant derivative to parental control
cells. The RAS pathway signature was significantly upreg-
ulated in ZR-75-1R cells (p = 2 × 10-7, mean fold change
= 1.4) suggesting that acquired resistance to AKT inhibi-
tion was associated with increased RAS signaling.
To further assess the possibility that acquired AKTi
resistance is driven by a switch from AKT signaling to
Ras pathway signaling we employed reverse phase protein
microarrays (RPPA) to compare phosphorylation status
of AKT and ERK as surrogate markers of the activity of
these pathways. Consistent with a switch from depen-
dence on AKT signaling to dependence on signaling
through RAS/ERK, the ZR-75-1R line showed decreased
phosphorylation of AKT and increased phosphorylation
of ERK (Figure 3C and 3D). Taken together, these data
support the hypothesis that elevated RAS pathway signal-
Figure 1 RAS signature score relationship to Kras mutation status. RAS signature scores relative to KRAS mutation status in (A) lung cancer cell 
lines, (B) breast cancer cell lines, and (C) lung tumors. The Y-axis shows the RAS pathway signature score relative to the mean of all samples in the 
experiment. Samples in red are KRAS mutant, samples in blue are KRAS wild-typeLoboda et al. BMC Medical Genomics 2010, 3:26
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ing as measured by our signature is a determinant of
resistance to AKT inhibition in breast cancer cell lines.
KRAS siRNA knockdown suggests that pathway signature is 
more predictive of dependence on RAS dependence than 
KRAS mutational status
Some cell lines with a Ras mutation do not appear to have
h i g h  l e v e l s  o f  R a s  s i g n a l i n g .  A  p o t e n t i a l l y  i m p o r t a n t
implication of this finding is that Ras mutations in can-
cers in some patients may not mean that these cancers
are dependent on Ras signaling. To understand the rela-
tionship between the RAS pathway signature and func-
tional dependence of cells on RAS/MEK/ERK-signaling,
we next used RNA interference (RNAi) to deplete KRAS
in lung cancer cell lines that exhibit high or low levels of
the RAS pathway signature within both KRAS mutant
and KRAS wild-type groups. The effect of KRAS knock-
down on viability was assessed in H2122 (KRAS mutant,
high RAS signature), H1155 (KRAS mutant, low RAS sig-
nature), Calu3 (KRAS wild-type, high RAS signature),
and H520 (KRAS wild-type, low RAS signature) cell lines.
These cell lines also showed differential sensitivity to
PD325901 (Figure 4). Upon KRAS knockdown the
growth and viability of H2122 and Calu3 were signifi-
cantly decreased (77% and 47% decrease; p < 0.0001),
whereas cell growth of H1155 and H520 were not mark-
edly diminished (7% and 0% decrease; Figure 4). KRAS
protein expression was reduced by at least 70% in all
lines. These results indicate that not all cell lines with a
KRAS mutation are dependent on RAS signaling, while
some KRAS wild-type cell lines are dependent on RAS
signaling. This supports the hypothesis that the RAS
pathway signature is a better measure of dependence on
RAS signaling compared to KRAS mutation status in
lung cancer cell lines.
Inhibition of MEK results in downregulation of the RAS 
pathway signature
The above results suggest that a core signature of RAS
pathway signaling has been identified. We hypothesized
that drug treatments known to inhibit key nodes of the
RAS signaling pathway should downregulate the RAS
pathway signature. To test this, we profiled 10 lung can-
cer cell lines before and after treatment with PD325901.
We selected cell lines known to exhibit elevated baseline
levels of the RAS pathway signature based on data shown
in Figure 2A. We used a dose of 0.1 μM (known to result
in efficacy in sensitive lines), and treated cells for 6 or 24
hours. As shown in Figure 5, inhibition of MEK results in
significant down-regulation of the RAS pathway signa-
ture across all cell lines. These results show that the RAS
pathway signature represents a gene expression module
that not only reflects RAS signaling at baseline, but is
responsive to RAS pathway inhibition. Therefore, the
RAS pathway signature could be used as a pharmacody-
namic biomarker for the assessment of pathway inhibi-
tion or activation after drug administration.
Low RAS pathway signature score is associated with a 
higher Cetuximab response rate in metastatic CRC
Given the prediction of response to MEK and AKT inhi-
bition in pre-clinical models and the translatability of the
RAS pathway signature to other tumor types, we next
sought to assess the predictive power of the RAS pathway
signature in a clinical setting. For this purpose, we com-
pared baseline levels of the RAS pathway signature to
clinical response to the EGFR inhibitor cetuximab in a
published dataset of metastatic colorectal carcinoma
patients [5]. 20/25 patients (80%) experiencing disease
control (stable disease, partial response, or complete
response) had RAS pathway signature scores < 0, repre-
senting a significantly larger proportion compared to
patients experiencing progressive disease (Figure 6,
Fisher's exact test p < 0.01). This finding is consistent
with the percent of patients experiencing disease control
with the KRAS wild-type genotype in this dataset (89%)
and with previously published findings that activated
KRAS leads to cetuximab resistance in colorectal cancer
[4,5,8]. As such, we conclude that the RAS pathway signa-
ture provides clinically useful information and warrants
Figure 2 RAS signature versus drug sensitivity or pathway activa-
tion. RAS signature score (Y-axis) versus cell sensitivity to a MEK inhibi-
tion (X-axis) across a panel of (A) lung or (B) breast cell lines. Lower 
numbers on the X-axis indicate increasing sensitivity. Cell lines circled 
in bold in (A) have a KRAS mutation but have low signature scores and 
are resistant to MEK inhibition. (C) RAS signature score (Y-axis) versus 
cell sensitivity to an AKT inhibitor (X-axis) across a panel of breast can-
cer cell lines. Lower numbers on the X-axis indicate increasing sensitiv-
ity. (D) phospho-MEK (Y-axis) versus RAS signature score (X-axis) across 
a panel of breast cancer cell lines. In all cases, the RAS signature score 
was calculated relative to the mean of all cell lines in the respective ex-
periment. R = Pearson correlation coefficient, p = the corresponding P-
value.Loboda et al. BMC Medical Genomics 2010, 3:26
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assessment as a potential predictive biomarker of
response in clinical trials involving RTK/PI3K or RAS
pathway inhibitors.
Ras signature distribution and prevalence in lung and 
breast tumors
As described above, using a RAS pathway signature score
of zero as a threshold (mean value across a population),
the RAS pathway signature has > 90% sensitivity for iden-
tification of KRAS mutations in lung and breast cancer
and identifies additional samples with apparent RAS
pathway activation in the absence of KRAS mutations. To
further explore the clinical utility of the RAS pathway sig-
nature in lung and breast cancer, we assessed the distri-
bution of and prevalence of RAS pathway signature
scores across breast (Expression Project for Oncology;
GSE 2109), and lung [21] tumors in publicly available
datasets. We then compared this to published data
regarding KRAS mutation. As shown in Figure 7A, the
RAS pathway signature is significantly higher in lung ade-
nocarcinoma compared to squamous (p < 10-8), with 76%
of adenocarcinomas exhibiting RAS signature scores
above zero compared to 30% of squamous lung tumors.
This is consistent with the known association between
KRAS mutations and lung adenocarcinomas, but sug-
gests that the true proportion of lung tumors with ele-
vated RAS pathway activity is larger than the ~15%
reported prevalence of KRAS mutations in lung cancer
[22,23]. In addition, the RAS pathway signature is signifi-
cantly higher in ER negative breast tumors compared to
other subtypes (p < 10-10, Figure 7B), with 79% of triple
negative tumors exhibiting RAS signature scores above
zero, compared to 17% of highly proliferative ER+ tumors
as measured by the genomic grade index signature [24].
As breast cancers are reported to have a very low preva-
lence of KRAS mutations [25], these results suggest that
ER negative breast tumors frequently have elevated RAS
pathway activity, even in the absence of frequent KRAS
mutation. Therefore, the RAS pathway signature signifi-
cantly expands the estimated prevalence of lung and
breast tumors with apparent RAS pathway activation, and
suggests that > 75% of lung adenocarcinomas and triple
negative breast cancers exhibit elevated RAS signaling.
Figure 3 Acquired resistance to AKT inhibition is associated with increased RAS signature. (A) generation of a cell line with acquired resistance 
to MK-2206 by culturing in increasing drug concentrations over 7 months. (B) Cells cultured in vehicle for 7 months remain sensitive to AKT inhibition. 
Cells with acquired resistance to MK-2206 show decreased pAKT (C) and increased pERK (D).Loboda et al. BMC Medical Genomics 2010, 3:26
http://www.biomedcentral.com/1755-8794/3/26
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Conclusions
Here we describe the identification of a gene expression
signature of RAS pathway activation that is coherently
expressed across colorectal, lung, and breast tumors. We
find that this RAS pathway signature is a high sensitivity
but low specificity predictor of KRAS mutation status, as
many cell line and tumor samples appear to have RAS
pathway activation in the absence of mutations in KRAS.
The RAS pathway signature predicts sensitivity to inhibi-
tion of MEK and resistance to inhibition of AKT in pre-
clinical models, predicts resistance to Cetuximab in met-
astatic colorectal cancer patients, and appears to be supe-
rior to KRAS mutation status for the prediction of RAS
dependence. In addition, we show that inhibition of RAS
signaling through the use of a small molecule inhibitor of
MEK induces a downregulation of the RAS signature.
Therefore, we conclude that the RAS pathway signature is
a transcriptional readout of RAS dependence that has
utility for drug response prediction that is superior to
KRAS mutation status.
In addition to utility as a pre-dose response predictor,
inhibition of the RAS pathway signature in response to
MEK inhibition indicates that the signature has utility as
a pharmacodynamic/pathway inhibition readout in
response to pharmacological interventions. Similarly, the
RAS pathway signature could also be used to map and
understand feedback regulation of RAS signaling after
pharmacological inhibition of RAS or PI3K signaling
components in different tumor contexts. For example,
Pratilas et al [26] recently showed that tumors with acti-
vating mutations in Braf are insensitive to feedback
downregulation of RAF signaling after MEK inhibition,
Figure 4 Effect of KRAS knockdown on viability of cells harboring a KRAS mutation. (A) KRAS mutant or (B) KRAS wild-type cells were selected 
for KRAS knockdown. Scatterplots indicate that these lines show variable sensitivity to MEK inhibition. The Y-axis shows RAS siganture score, and the 
X-axis show cell sensitivity to MEK inhibition. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines in red text were treated with siRNAs 
targeting KRAS. Western blots were performed for KRAS and B-actin. Control = Dharmacon non-targeting siRNA pool; KRAS = siRNA targeting KRAS, 
none = no transfection. Bar charts show viability as measured by the ATP vialight assay. The percent viability relative to the control siRNA is shown. R 
= Pearson correlation coefficient, p = the corresponding P-value.Loboda et al. BMC Medical Genomics 2010, 3:26
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and thus are dependent on MEK/ERK for survival. Future
studies should include the assessment of feedback regula-
tion of RAS and PI3K pathway components in various
tumor contexts to make predictions about which inhibi-
tor(s) should be used in which populations.
Because the RAS pathway signature was identified on
the basis of coherent regulation across multiple tumor
types we hypothesize that the RAS pathway signature will
have utility beyond colorectal cancer, where currently the
strongest clinical data exist regarding the prediction of
d r u g  r e s po n s e  b y  KRAS  m u t a t i o n s.  T h e  RAS  p a t h wa y
signature approximately doubles the population of "RAS
active" lung tumors, and identifies triple negative breast
tumors as the breast cancer subset with the highest pre-
dicted RAS pathway dependence. As such, is it likely that
the RAS pathway signature will have the highest value
proposition in lung and breast tumors. Because the prev-
alence of KRAS mutations in breast cancer is very low,
yet the RAS pathway signature is coherently expressed
and predicts MEK inhibitor sensitivity and AKT inhibitor
resistance in breast cancer cell lines, the RAS pathway
signature may have the most immediate value for clinical
development in breast cancer. One clear implication of
this work is that inhibitors of MEK should be clinically
tested in triple negative breast tumors and NSCLC ade-
nocarcinomas. Conversely, inhibition of PI3K pathway
components like AKT without inhibition of RAS signal-
ing is unlikely to be efficacious in triple negative breast
cancers or lung adenocarcinomas, regardless of KRAS
mutation status.
What could be driving elevated RAS signature scores in
the absence of KRAS mutations? One possibility is that
activating mutations in other canonical RAS pathway
components could be responsible for elevated RAS signa-
ture in at least a subset of samples with wild-type KRAS.
One candidate driver is mutant B-raf [8]; however, given
the relatively high prevalence of KRAS wild-type samples
with elevated RAS signature scores, it seems unlikely that
this could be the sole explanation. Other candidate altera-
tions include mutation sin H-ras, activation of receptor
tyrosine kinases like EGFR, deletion of GTPase activating
proteins, and other mechanisms (reviewed in [27]). Fur-
ther work will be required to elucidate the key driver(s) of
elevated RAS signature in various tumor contexts. If such
drivers could be identified, it may be possible to design
inhibitors of these drivers and design a tumor context-
specific approach for targeting RAS signaling in tumors.
Methods
Cell culture and tumor sample sets
For cell lines used to identify the "down" arm of the signa-
ture and to assess the sensitivity of the RAS pathway sig-
nature for KRAS mutation status: cell lines were grown in
ATCC recommended media in tissue culture flasks, RNA
was extracted, and gene expression profiling was per-
formed on Agilent arrays as described below.
For cell lines used to assess the relationship between
the RAS pathway signature, pMEK/pERK, and MEK/
AKT inhibitor response: Lung tumor-derived cell lines
Figure 5 Impact of MEK inhibition on the RAS signature across 10 
lung cancer cell lines. The Y-axis shows the RAS signature score in 
drug treated cell lines relative to vehicle treated controls.
Figure 6 Waterfall plot of RAS signature score in patients who ex-
perienced disease control (blue) or progressive disease (red) after 
Cetuximab therapy. The Y-axis shows RAS signature score relative to 
the mean of all tumors in this dataset. Fisher's exact test p-value for the 
difference between the disease control and progressive disease 
groups is shown. Data is derived from [5], and includes all patients with 
known response.
Figure 7 RAS signature distribution across non-small cell lung (A) 
and breast (B) cancer subsets. The Y-axis shows RAS signature score 
relative to the mean of all non-small cell lung (A) or breast (B) tumors 
in the dataset. For (B), GGI = genomic grade index [32]. GGI- = ER pos-
itive, GGI negative (surrogate for luminal A). TN = triple negative. Her2 
+ = high expression of Her2. GGI + = ER positive, GGI high (surrogate 
for luminal B).Loboda et al. BMC Medical Genomics 2010, 3:26
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were obtained from various commercial vendors (ATCC,
ECACC, DSMZ, HSRRB, IBL). Cells were cultured in
media recommended by the vendor in tissue culture
flasks. Generally, cells were passaged upon reaching 75%
confluence. Sensitivity of cells to PD325901 (a derivative
of CI-1040 [28], a potent and selective noncompetitive
inhibitor of MEK1 and MEK2) and MK-2206, an allos-
teric inhibitor of AKT1, AKT2, and AKT3 [29] was deter-
mined at 8 concentrations using Cell Titer Glo (Promega;
Madison, WI). Drug sensitivity values were corrected for
basal growth rate of cells in order to avoid artifacts
related to differential doubling times across cell lines.
Given that stratification of the cell lines' relative
responses is paramount, the metric should maximize the
power to discriminate between individual cell line's
responses. Our approach was to use a computational
algorithm to find the concentration at which the popula-
tion of cell lines' responses exhibited maximal variation.
This was done by finding the maximum value of the vari-
ance across the concentration range tested. Cell line sen-
sitivity was determined at this dose for each cell line in
the panel and this was the primary metric of response
used in for analyses. RNA was extracted from untreated
cells, and gene expression profiling was performed on
Affymetrix arrays as described below. Phospho-MEK and
phospho-ERK levels were measured using reverse phase
protein arrays as described in [20].
Downregulation of the RAS signature by MEK inhibi-
tion: Lung cancer cell lines were grown in standard
media. Vehicle (DMSO) or PD325901 (0.1 μM) was
added to cells for 6 or 24 hours. RNA was extracted, and
gene expression profiling was performed on Affymetrix
a r r a y s  a s  d e s c r i b e d  b e l o w .  D a t a  f r o m  e a c h  p o s t - d o s e
group was normalized to the cell line-matched vehicle
control.
For prediction of KRAS mutation status in lung tumors:
48 primary tumors were excised, frozen and embedded in
OCT compound embedding medium. Tumors were mac-
rodissected with the goal of attaining 70% tumor content
before nucleic acid extraction for molecular profiling.
Lung tumor mutation data were generated using mass
spectrometry-based genotyping (OncoMap) [30]. RNA
was extracted, and gene expression profiling was per-
formed on Affymetrix arrays as described below.
mRNA profiling
RNA extraction: Tissus and cell lines were homogenized
within their source cryopreservation tubes using a Poly-
tron with disposable rotostator probes. Material was
homogenized in 750 to 1000 uL of 100% TRIzol. 100%
Chloroform was added to the TRIzol/GITC lysate (1:5
ratio) to facilitate separation of the organic and aqueous
components using the phaselock (Eppendorf) system.
The aqueous supernatant was further purified using the
Promega SV-96 total RNA kit, incorporating a DNase
treatment during the procedure. Isolated total RNA sam-
ples were then assayed for quality (Agilent Bioanalyzer)
and yield (Ribogreen) metrics prior to amplification.
Samples profiled on Affymetrix arrays: Samples were
amplified and labeled using a custom automated version
of the NuGEN Ovation WB protocol. Hybridization,
labeling and scanning using Affymetrix ovens, fluidics
stations and scanners following the protocols recom-
mended (NuGEN). Sample amplification, labeling, and
microarray processing were performed by the Rosetta
Inpharmatics Gene Expression Laboratory in Seattle,
WA. Samples were hybridized to the Rosetta/Merck
Human RSTA Custom Affymetrix 1.0 microarray (GEO
accession number GPL6793). Hybridization of affyme-
trix chips was done following the standard Affymetrix
protocol. Generated .CEL files were then processed using
the RMA algorithm as implemented in Affymetrix Power
Tools (APT) package, using default settings and standard
CDF file. Generated probeset intensities were then log10-
transformed. Signature scores were calculated by averag-
ing probesets whose gene symbols mapped to the gene
sets for the "up" and "down" arms of the signature gene
sets, and subtracting score for the "down" arm from the
"up" arm".
Samples profiled on Agilent arrays: Samples were
amplified and labeled using a custom automated version
of the 5 μg RT/IVT protocol described in [31]. Sample
amplification, labeling, and microarray processing were
performed by the Rosetta Inpharmatics Gene Expression
Laboratory in Seattle, WA. Samples were hybridized to
the Rosetta/Merck Human RSTA custom Agilent 3.0
array (GEO accession number GPL3991).
Generation of the RAS signature and assessment of 
signature coherence
We identified the "superset" of genes potentially sensitive
to RAS deregulation by assembling the genes from the
"up" arms (genes upregulated as signaling through the
pathway increases) of three different publicly available
RAS pathway signatures [9,12,17]. This RAS superset
(consisting of 812 genes) was analyzed in publicly avail-
able cohorts of lung, colon, and breast tumors (GEO
accession number GSE2109) as well as lung cancer cell
lines https://array.nci.nih.gov/caarray/project/woost-
00041. For each dataset, we identified a coherent gene
expression module: a subset of genes whose gene expres-
sion profiles clustered together. The relationship between
genes was assessed using two-dimensional clustering of
the Pearson correlation matrix (using complete linkage
and Euclidean distance metric as hierarchical clustering
parameters). The identified gene subset is characterized
by the mean/median Pearson correlation between its
members of 0.40. By intersecting all four datasets, aLoboda et al. BMC Medical Genomics 2010, 3:26
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coherent module consisting of 105 genes from the RAS
superset was observed in all datasets. The genes that
belonged to the module across all the datasets were
selected as the "up" arm of our signature. Genes signifi-
cantly anitcorrelated with the "up" arm (Pearson correla-
tion coefficient at least -0.4) across an internal lung
cancer cell line panel were selected as the "down" arm for
subsequent assessment of coherence and calculation of
the signature score.
The assessment of coherence is based on the opposite
behavior the "up" arm, which is upregulated, and the
"down" arm, which is downregulated, as signaling
through the pathway increases. The purpose of coher-
ence analysis is to show the statistical significance of the
difference between the "up" and "down" arms of a signa-
ture in a new dataset. For coherence analysis, two correla-
tion coefficients were calculated for all of the genes in
both the "up" and "down" arms. First, the correlation
between each gene in the "up" arm and the average of all
genes in the "up" arm is calculated. Second, the anticorre-
lation between each gene in the "up" arm and the average
of all genes in the "down" arm is calculated. This is
repeated for genes in the "down" arm. If the signature is
coherent, most of the genes from each arm should corre-
late with the corresponding arm average and anticorre-
late with the average of all genes in the opposite arm. A
Fisher exact test is calculated for correlation within and
between arms of the signature to assess the significance
of signature coherence in a new dataset. Coherence of our
signature was tested in independent lung (GSE3141),
colon (GSE5851), and breast (GSE2845) gene expression
datasets.
Acquired resistance to MK-2206
We generated resistant clones of a MK-2206 sensitive
breast cancer cell line, ZR-75-1 (EC50 < 200 nM), by
exposing it to increasing concentrations of MK-2206 for a
period of 7 months. We obtained populations of MK-
2206 resistant cells by initially treating the cells at a low
concentration of MK-2206 (20 nM) and incrementally
increasing the concentration as the growth rate of
exposed cells reached that of cells grown in the presence
of vehicle alone. Cells exhibiting robust growth in the
presence of high MK-2206 (> 2 μM or 10× the original
EC50), were grown in the absence of drug for three weeks
and then confirmed as AKTi resistant in a cell prolifera-
tion assay. To control for potential non-AKT-related
mechanisms of drug resistance such as up-regulation of
drug efflux pumps, cells were also tested for sensitivity to
taxol. Expression profiles of resistant derivatives and
parental controls were generated and compared using
Affymetrix arrays as described above.
KRAS siRNA
Cells (3 × 105) were seeded in 6 well plates (Costar) and
transfected with KRAS and control siRNA smartpools
from Dharmacon using DharmaFECT1 transfection
reagent (Dharmacom #T2001-01). 18 hrs post transfec-
tion, cells were trypsinized and seeded in 96 well plates (4
× 10e3 cells/well) for the viability assay (96 hrs) or in 6
well plates for western blot analysis. Cell viability was
measured using CellTiter-Glo according to manufacturer
instructions (Promega; Madison, WI). For Western Blot
analysis, cells were lysed 5 days post-transfection and
protein levels were detected using the following antibod-
ies: KRAS (Santa Crus #SC 30), pERK (CST #4695),
pAKT(CST #4058) and β-actin (CST #4970).
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tion is expected.
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Additional file 3 RAS signature genes. Genes comprising the RAS signa-
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